Helen Shih, MD, MS, MPH, FASTRO, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.
Helen Shih, MD, MS, MPH, FASTRO, medical director, MGH Proton Therapy Centers; director, CNS & Eye Service; and program Director, Proton Therapy Fellowship, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.
Transcript
What risks have you seen associated with treating or waiting to treat patients with low-grade gliomas?
It's geography, it's the location. So some parts of the brain are relatively safe to treat, other parts of the brain are near radiation-sensitive structures. And if the radiation dose that's needed to treat a tumor is very close to a radiation-sensitive structure, there's a risk of injuring or impairing the function of something else, such as hearing or vision, or it can just lead to symptoms of like—if we’re treating a larger area or near certain areas—you can have a higher risk of nausea, feeling unwell.
Most of those symptoms during the time of radiation are temporary, thankfully, and do resolve. Even things like hair loss, you know, the hair, the scalp, the hair follicles will determine whether or not hair loss during radiation is going to be temporary or permanent, or something in between. So a lot of it depends on location.
I think another consideration is when you see someone with a low-grade glioma at the first diagnosis, that's the smallest the tumor is ever going to be. Some of the treatments may be able to reduce the density of the tumor and kill off tumor cells, so that there is literally less tumor cells, but the footprint of where the tumor extends to tends to be the same, and then over time it will increase, as it tends to spread beyond the initial volume at time of initial diagnosis. So if you wait on giving radiation treatment, sometimes it's a good thing because you're delaying or avoiding side effects associated with radiation.
But on the flip side, it can also grow beyond the initial volume and then you eventually get radiation. You can actually have more side effects if it's now growing toward, for example, the pituitary gland, which it wasn't at initially, and if that later involves collateral radiation of the pituitary gland, that can cause hormonal or endocrine problems that may not have occurred if you treated the patient first diagnosis.
Organizational Factors Associated With Variation in Primary Care Providers in ACOs
April 8th 2025A higher percentage of accountable care organization (ACO) primary care providers was associated with physician leadership, upside financial risk, and financial compensation of physicians tied to performance measures.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Managing Skin Conditions: Highlighting Ruxolitinib Cream, Phototherapy Efficacy and Cost
April 8th 2025Research presented at the 2025 Academy of Managed Care Pharmacy annual meeting analyzed real-world treatment outcomes for dermatologic conditions, specifically highlighting the efficacy of ruxolitinib cream for atopic dermatitis and the potential for phototherapy to delay costly biologic initiation.
Read More
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More